

APPENDIX

Market Share of Drug Classes and Average Length of Treatment for mBC by Line of Treatment and Biomarker Subgroup in Spain[13]

Treatments	HER2-/ HR+						HER2+/ HR+						HER2+/ HR-						Triple negative											
	1st line		2nd line		3rd line		1st line		2nd line		3rd line		1st line		2nd line		3rd line		1st line		2nd line		3rd line							
	Treatment share	Average length of treatment (months)	Treatment share	Average length of treatment (months)	Treatment share	Average length of treatment (months)	Treatment share	Average length of treatment (months)	Treatment share	Average length of treatment (months)	Treatment share	Average length of treatment (months)	Treatment share	Average length of treatment (months)	Treatment share	Average length of treatment (months)	Treatment share	Average length of treatment (months)	Treatment share	Average length of treatment (months)	Treatment share	Average length of treatment (months)	Treatment share	Average length of treatment (months)						
Overall patient population																														
Anthracyclines	12%	7.4	8%	5.6	8%	4.6	1%	5.0	3%	5.0	6%	5.0	2%	5.0	3%	6.5	7%	5.5	19%	7.3	10%	5.4	8%	4.4						
Taxanes	29%	7.6	21%	6.2	16%	4.9	78%	11.0	16%	7.2	10%	6.1	86%	12.1	21%	7.3	15%	6.0	71%	7.7	21%	5.6	12%	4.4						
Anti-metabolites	6%	6.8	21%	6.4	21%	4.7	2%	10.3	19%	7.3	16%	6.3	2%	10.7	20%	7.9	20%	6.5	11%	7.1	24%	5.8	19%	4.4						
Vinca Alkaloids	3%	6.4	13%	5.4	15%	4.3	9%	11.9	18%	8.3	20%	6.5	10%	12.3	18%	7.6	18%	6.0	3%	5.3	13%	5.6	14%	4.3						
Eribulin	0%	0.0	3%	6.5	13%	4.8	0%	0.0	1%	6.0	8%	6.3	0%	0.0	1%	6.0	4%	5.5	1%	11.0	12%	6.1	27%	4.4						
Alkylating drugs	2%	6.3	2%	5.3	8%	4.2	1%	6.0	3%	5.5	3%	5.0	1%	5.0	1%	5.0	1%	6.0	4%	5.7	4%	5.0	8%	4.2						
Platinum agents	2%	6.0	2%	5.0	6%	4.8	0%	0.0	2%	6.0	3%	5.3	0%	0.0	1%	5.0	5%	5.3	15%	7.5	27%	5.9	14%	4.4						
Everolimus	2%	9.3	16%	6.6	15%	5.8	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0						
Targeted therapies - anti HER2	0%	0.0	0%	0.0	0%	0.0	98%	14.4	95%	9.7	84%	7.4	99%	14.2	93%	10.0	87%	7.3	0%	0.0	0%	0.0	0%	0.0						
Targeted therapies - other (bevacizumab)	5%	8.8	5%	7.0	4%	6.0	0%	0.0	0%	0.0	6%	5.0	0%	0.0	0%	0.0	0%	0.0	29%	9.4	7%	5.5	2%	4.0						
Premenopausal patients																														
Oophorectomy	26%	-	23%	-	28%	-	13%	-	15%	-	5%	-	0%	-	0%	-	1%	-	0%	-	0%	-	0%	-						
Ovarian radiotherapy	2%	-	1%	-	1%	-	1%	-	1%	-	0%	-	0%	-	0%	-	0%	-	0%	-	0%	-	0%	-						
Gonadorelin (LHRH) analogues	36%	10.9	25%	7.0	17%	5.0	14%	10.3	16%	6.3	10%	5.3	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0						
Selective estrogen receptor modulators	39%	10.6	8%	6.2	5%	4.7	17%	10.3	5%	6.8	3%	5.3	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0						
Selective estrogen receptor down regulator	3%	12.5	14%	7.2	24%	5.5	1%	15.0	6%	6.6	7%	5.3	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0						
Aromatase inhibitors	26%	11.2	32%	6.8	10%	4.8	8%	10.8	16%	7.4	9%	5.2	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0						
Postmenopausal patients																														
Oophorectomy	0%	-	0%	-	0%	-	0%	-	0%	-	0%	-	0%	-	0%	-	0%	-	0%	-	0%	-	0%	-						
Ovarian radiotherapy	0%	-	0%	-	0%	-	0%	-	0%	-	0%	-	0%	-	0%	-	0%	-	0%	-	0%	-	0%	-						
Gonadorelin (LHRH) analogues	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0						
Selective estrogen receptor modulators	6%	10.7	5%	7.3	11%	4.8	2%	11.3	2%	7.0	3%	5.5	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0						
Selective estrogen receptor down regulator	22%	11.1	37%	7.4	21%	5.3	7%	10.3	18%	6.1	6%	4.8	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0						
Aromatase inhibitors	51%	11.9	25%	7.0	18%	5.6	17%	9.0	6%	6.3	11%	4.8	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0	0%	0.0						

References of Clinical Trials Used to Estimate Adverse Event Rates

O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. *Ann Oncol*. 2004;15(3):440-449.

Ejlertsen B, Mouridsen HT, Langkjer ST, Andersen J, Sjostrom J, Kjaer M. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). *J Clin Oncol*. 2004;22(12):2313-2320.

Heidemann E, Stoeger H, Souchon R, et al. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. *Ann Oncol*. 2002;13(11):1717-1729.

Palmieri C, Misra V, Januszewski A, et al. Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer. *Clin Breast Cancer*. 2014;14(2):85-93.

Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. *J Clin Oncol*. 2001;19(22):4216-4223.

Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. *J Clin Oncol*. 2005;23(25):6019-6026.

Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. *J Clin Oncol*. 2008;26(30):4883-4890.

Iwata H, Masuda N, Ohno S, et al. A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer. *Breast Cancer Res Treat*. 2013;139(2):441-451.

Wolff AC, Lazar AA, Bondarenko I, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. *J Clin Oncol*. 2013;31(2):195-202.

Taylor CW, Green S, Dalton WS, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. *J Clin Oncol*. 1998;16(3):994-999.

Inoue K, Nakagami K, Mizutani M, et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. *Breast Cancer Res Treat*. 2010;119(1):127-136.

Blackwell KL, Pegram MD, Tan-Chiu E, et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. *Ann Oncol*. 2009;20(6):1026-1031.

Cortes J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. *J Clin Oncol*. 2012;30(14):1594-1600.

Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. *Semin Oncol*. 2003;30(5 Suppl 16):117-124.

O'Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. *J Clin Oncol*. 2014;32(34):3840-3847.

Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *New Eng J Med*. 2012;366(6):520-529.

Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol*. 2010;28(35):5132-5139.